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ABSTRACT 
The purpose of this registry study was to provide an overview of trends and results of liver 
transplantation in Europe from 1968 to 2016. 
This data on liver transplantation (LT) was collected prospectively from 169 centers from 32 
countries, in the European Liver Transplant Registry (ELTR) beginning in 1968. This 
overview provides epidemiological data, as well as information on evolution of techniques, 
and outcomes in liver transplantation in Europe over more than 5 decades; something that 
cannot be obtained from only a single center experience.  
 
INTRODUCTION 
Background of the European Liver Transplant Registry 
Created in 1986, the ELTR has collected the data of liver transplantation (LT) from 175 
centers all over Europe since 1968. The registered data represents more than 95% of the 
overall European data compared to the published official figures [1]. 
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Questionnaire 
The ELTR questionnaire includes data on indications for LT, donors and recipients 
characteristics, technical aspects of LT (with reduced, split, domino, live and non-heart 
beating donors), initial and current regimen of immunosuppression, patient outcomes, and 
cause of death or graft failure. The ELTR has developed an online application (Electronic 
Data Capture – EDC) for collecting data. A Web-based module was developed to allow for 
real-time data capture. Software, questionnaires, validation routines and statistics are located 
on a central server, which can be accessed by the participating centers with a standard 
internet browser [2]. 
To avoid an overlap in case of multiple diagnoses, the ELTR has two variables to report the 
diagnosis (Disease1 & Disease2) and an open field for specification in case a diagnosis is not 
available in the official pull-down menu, or in case there are more than two combined 
diagnoses. A standard procedure was stated accordingly for the data entry and their analysis 
in each condition. 
Quality control of the data 
The data-entry process is dynamically controlled. The data are subjected to routine checks for 
completeness, consistency, and range. Comprehensive logical intra- and inter-updates are 
performed. In addition, a control of the good adequacy between ELTR questionnaire and 
patient charts is performed by randomly conducted audit visits to the centers. The ELTR 
audit visits have been continuously conducted since 1998 with, initially 10 randomly selected 
centers per year up to the year 1999, and 5 centers per year since 2000. Two auditors perform 
the visit with the condition that both are not from the visited country. Ten percent of center’s 
files, with a minimum of 20 and a maximum of 50, are analyzed to check data for 
completeness and consistency. The audit visits serve also to train staff members, and to 
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introduce amendments in the procedure. It is also the opportunity to meet with the staff of 
centers, something that is valuable for creating a team spirit. The ELTR is considered as the 
pioneer of external audit visits of a scientific registry. The audit report is sent confidentially 
to the head of the center with all the discrepancies noted, and the recommendations necessary 
to improve the data entry included. The results of all center audits are presented during the 
ELTR biennial workshops, where all the contributing centers are invited.  A recent analysis 
of the ELTR audit data (38 centers from 16 countries, 57,575 variables from 1458 patient 
files, from 2010 to 2016) showed that the overall rates of completeness and consistency were 
94.5% and 97.3%, respectively. Audit visits are an indicator of the quality of data, and 
represent one of the pillars of the ELTR. These results have indicated that ELTR data are 
reliable, and the scientific results of ELTR can be considered credible and representative of 
LT in Europe [3-6].  
Partnership with Organ Sharing Organizations (OSOs)  
The ELTR has established agreements with the main national and international OSOs: United 
Kingdom Transplant Service Support Authority – UK NHS Blood and Transplant, Spanish 
Organizacion Nacional de Trasplantes - ONT, Scandinavian Scandiatransplant - SKT, Dutch 
Transplant Foundation - NTS, Eurotransplant Foundation - ET, French Agence de la 
Biomédecine – ABM to exchange data collected from European Centers and to cross check 
common data between OSO and ELTR. 
Source of the data  
There are two sources of ELTR data; 72% of data (63% of centers) are shared with the OSOs 
and 28% of data (37% of centers) are directly entered into the ELTR EDC platform. Some 
variables were added to the questionnaire, and some definitions have changed since the 
registry was created in 1986. To adapt the ELTR to these evolutions, an experts committee 
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was appointed to oversee the standardization of the questionnaire. The ELITA (European 
Liver and Intestine Transplant Association) board and the OSOs share this concern and are 
also attentive to all the evolutions. 
Previous ELTR achievements  
The ELTR regularly carries out thematic studies related to the different fields of LT. These 
studies minimize the potential biases, by assessing interactions between confounding factors 
and identification of independent predictors among all the ELTR variables that can have an 
impact on the outcome. A sample of these studies is cited in the references of the manuscript. 
With reports concerning LT for specific hepatic diseases [7-24], analysis of the impact of the 
type of preservation solution [25], and of the immunosuppressive regimen on the patient 
outcome [26], ELTR has helped develop risk models for mortality following liver–
transplantation [27, 28].  Owing to the large cohort of patients, the exhaustiveness, and 
quality of the data, and the long follow up provided by the ELTR, the results are really 
representative of liver transplantation in Europe.  
The objective of this paper is to report these results and their evolution in adults as well as in 
pediatric recipients. 
  
PATIENTS AND METHODS 
The whole data since 1968 was considered initially to show the evolution of results of LT in 
Europe since its initial development. The rest of analysis was then undertaken considering 
two different periods: (a) January 1988 to December 2016 (147,161 LT – 127,851 patients) 
[January 1988 was chosen corresponding to the introduction and widespread use of 
cyclosporine-based immunosuppression, and standardization of the surgical procedure], (b) 
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the last 15-yr period data from January 2002 to December 2016 (99,562 LT – 91,183 
patients) to give a more recent evaluation of LT results in Europe. 
Data were generally analyzed as a whole (except for some variables), without making a 
distinction between adult and pediatric population, the latter representing 10% of LT in 
Europe.  
Kaplan–Meier analysis was used to estimate graft and patient survival stratified by conditions 
group; statistical analyzes were performed using the log–rank test (p<0.05 as significant) with 
SAS® Version 9.1.3 Entreprise Guide version 5.1 (Copyright© 2012 by SAS Institute Inc., 
Cary. NC. USA). The dynamics of data control was continued during the statistical analyzes. 
Calculation of survival rates was determined by the actuarial method. 
  
RESULTS  
From May 1968 to December 2016, the ELTR has collected data concerning 146,782 liver 
transplantations (LTs) in 132,466 patients, from 169 Centers, and 32 countries (Figure 1). 
This data gives a comprehensive overview of the status and evolution of LT in Europe. Both 
the number of transplant centers and the annual number of LT’s performed in Europe have 
gradually increased since the ELTR was created (Figure 2). However, after an exponential 
increase from the eighties, a plateau seems to have been reached in recent years with about 
7,300 LTs performed all over Europe annually 
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 Main indications of LT in Europe 
The main indications for LT in Europe with the corresponding graft and patient survival rates 
at 1, 5, 10 and 15 years in the whole ELTR population and in the last 15 years cohort are 
listed in Table 1. Twenty-year survival is provided for the whole ELTR population. Cirrhosis 
was the most frequent indication (50%), mainly related to either viral infection (22% with 
12% of hepatitis C virus (HCV) infection and 5% of hepatitis B virus (HBV) infection), or to 
alcohol abuse (19%). Combined viral and alcoholic (ALD) cirrhosis represented 2.4% of 
indications, with 2% of HCV-ALD. Cirrhosis is followed by three major indications: primary 
liver tumors (17%, predominantly hepatocellular carcinoma – HCC, 15%), cholestatic liver 
diseases (10%), and acute hepatic failure (9.1%, 2% of which are virus-related, 2.4% drug 
related, 0.3% toxic non-drug related and 4.4% of unknown cause). The most common 
etiologies of the underlying cirrhosis in HCC patients were HCV (43%), ethanol abuse (27%) 
and HBV (16%). Cholestatic diseases included primary biliary cirrhosis (5%) and primary 
sclerosing cholangitis (5%). Biliary atresia (4%) represented the major congenital biliary 
disease. Metabolic diseases represented 6% of all the indications with three major indications 
being familial amyloidotic polyneuropathy, Wilson disease, and alpha-1-antitrypsin 
deficiency (1% each). Budd-Chiari and benign liver tumors (mainly polycystic disease) 
represented only 1% of the indications for LT. Secondary liver tumors (mainly 
neuroendocrine) represented 0.5% of LT’s. 
 
Indications for Pediatric liver transplants 
The proportions of the main indications for LT are differently distributed according to the age 
of recipients. While biliary atresia and metabolic diseases were the major indications in 
pediatric patients (≤18 years), cirrhosis with end stage liver disease, and cancer were the 
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major indications in adults. An exponential increase in the proportion of cancer cases was 
noted with recipient age. Acute liver failure (ALF) mostly of unknown cause was frequent in 
young patients, with the highest incidence at 18-24 years. 
 
Evolution of indications 
The percentage of main indications has significantly changed with time (Figure 3). Whereas 
cancers represented 12% of indications before 1997, their incidence has doubled in the last 
decade to represent currently more than 24%.  Metabolic diseases and primary sclerosing 
cholangitis have slightly increased during the last decade. Conversely, while comparing the 
last decade with the previous one, we found that the proportion of cirrhosis alone, ALF and 
primary biliary cholangitis decreased. The decrease in cirrhosis is mainly due to the decrease 
in HCV cirrhosis, and the reduction of ALF cases is mainly due to the decline of ALF of 
unknown origin.  
 
Survival according to the indication for LT 
When all indications were considered, during the entire study period, patient survival rates 
were 83% at 1 year, 71% at 5 years, 61% at 10 years, 51% at 15 years, and 41% at 20 years.  
After an improvement between 1985 and 2000, the survival of patients appears to be 
relatively steady since 2000 (Figure 4). 
The improvement in survival was seen in patients transplanted for all the three main 
indications; cirrhosis (Figure 5A), fulminant hepatitis (Figure 5 C) but was particularly 
regular in LT for cancers (Figure 5C). The 5-year patient survival rate was significantly better 
for cirrhosis (71%) than for primary liver tumors (64%, p<0.001) and acute hepatic failure 
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(65%, p<0.001). HBV and HCV co-infection had a better 5-year survival (80%) compared to 
mono-infection with HCV (64%) or HBV (74%). The better 5-year survival rates obtained in 
metabolic diseases (79%), cholestatic disease (79%) and congenital biliary disease (85%), are 
partly explained by the high percentage of children in these groups.  The survival rates in 
adults and children were respectively, 76% and 85% for metabolic diseases, 79% and 86% 
for cholestatic disease and 82% and 85% for congenital biliary disease. The details of 
survival rates at 1, 5 and 10, 15 and 20 years according to the primary indication are listed in 
Table 1. 
Although the 5-year survival improved in the 15 recent years for all the indications, the most 
important gain in survival was observed in LT for primary liver tumors (67%), liver 
metastases (61%) and acute liver failure (69%). 
Since the adoption of the transplantation Model for End-stage Liver Disease score (MELD) 
score in the majority of European countries in 2006-2007, the proportion of patients with a 
high MELD score (>30) at transplant has almost doubled. However, the survival of these 
patients is less optimal, especially for those with a MELD score at transplant higher than 40 
(Figure 6).  
 
Survival according to donor and recipient characteristics 
Donor characteristics 
The majority of donors were male (57%). Fifty-eight percent were younger than 50 years, 
whereas 23% were older than 60 years. A gradual increase of the percentage of livers coming 
from septuagenarian donors was observed (1% in 1993, 10% in 2005 and 20% in 2015) in 
relation to the increasing gap between a growing waiting list and a relatively stable donor 
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pool (Figure 7). Graft survival when organs were procured from donors younger than 55 
years was significantly better than that with organs from donors older than 65 years (67% vs. 
60% at 5 years, p<0.0001) (Figure 8). However, attention should be paid to the donor to 
recipient matching to interpret these results, older donor livers being more frequently 
transplanted to older recipients. 
Recipient age 
In addition to the better 5-year survival of pediatric versus adult LT recipients (90% vs. 81%, 
p<0.0001), an influence of age was noted for adult recipients.  Survival rates were 75% for 
adults aged 18 to 45 years, 71% for 46-60 years, 65% for 60-70 years, and 60% for 
septuagenarians. However, average age of transplanted recipients has increased steadily 
during the last decade, and patients older than 60 years, who represented less than 5% in the 
1980s, currently represent more than 30% of transplant recipients (Figure 9). Older grafts are 
more frequently transplanted to older recipients. Septuagenarian recipients received 43% 
grafts older than 60-years and only 12% of grafts younger than 30-years, explaining at least 
in part, the difference in survival between recipient age groups (Figure 10). Importantly, LT 
offered a 10-year survival up to 40% in septuagenarians. 
Blood group compatible and incompatible transplants 
In elective conditions, 93% of LTs were isogroup, and 6.5% were compatible, whereas in 
emergency, 3% of LT were incompatible. In both elective and emergency conditions, 
isogroup LTs had a better 5-year survival compared to compatible or incompatible LTs (66% 
vs. 62% vs. 57%, p<0.0001) and (56% vs. 53% vs. 28%, p=0.001), respectively. However, 
the use of these incompatible grafts in emergency indications allows a 38% survival rate at 1 
year in patients otherwise expected to have a fatal outcome. 
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Survival according to surgical technique 
Auxiliary grafts represented 0.5% of overall LTs with a similar graft survival as compared to 
non-auxiliary grafts in urgent (5-year survival rates: 57% vs. 56%), and elective (66% vs. 
69%) indications. The shorter the ischemia time; the better was the graft survival. Five-year 
survival was 70% for ischemia time <6 hours, 67% for 6-12 hours, 63% for 12-15 hours, and 
58% for >15 hours.  The use of static graft preservation solutions evolved during three 
distinct periods: period 1 before 1990 with the main use of Collins solution; period 2 between 
1990 and 2000 with the almost exclusive use of UW (University of Wisconsin); period 3 after 
2000 with an increasing use of new solutions with different characteristics such as HTK, 
Celsior, IGL 1 or SCOT (Figure 11). Overall graft survival at 5 years for the main solutions 
was 74% for Celsior and IGL 1, 72% for UW and 69% for HTK (Figure 12). If only partial 
livers were considered, survival was 83% for IGL 1, 79% for Celsior, 77% for UW and 71% 
for HTK. 
Alternative procedures to LT using full size livers from donors after brain death (DBD) have 
been increasingly used in recent years. While representing less than 10% before 2000 they 
concerned more than 20% of overall LT procedures after 2000 and 75% in pediatrics. A 
differentiation between adult and pediatric patients is necessary; because alternative 
techniques are used differently in each population and the patient’s outcome may differ. 
 
Adult population 
Before 1994, alternative procedures concerned mainly reduced and split livers. Domino grafts 
were introduced in 1994 and living donation in 1996. Donation after cardiac death (DCD) 
was introduced in 2001 and since then, has gradually increased to represent currently almost 
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40% of the alternative procedures in adults. Consequently, the proportion of split, living, 
reduced and domino grafts has decreased.  The latter two modalities are really associated 
with the more significant decrease (Figure 13A). Ten-year graft survivals for each type of 
graft are summarized in Figure 13B. Survival at 5 years was similar between DBD full size 
grafts, split liver, domino and DCD (66% to 67%), but higher than that of reduced grafts and 
living donors (63% in both).  
Pediatric population 
Before 1988, alternative procedures concerned mainly reduced livers. Split livers were 
introduced in 1988 and living donation in 1991 and since their introduction both have 
gradually increased to represent currently more than 90% of the alternative procedures in 
children (Figure 14A). Ten-year graft survivals for each type of graft are summarized in 
Figure 14B. Survival at 5 years was similar between DCD and living donors (80% and 78%, 
respectively), but higher than that of DBD full size grafts, split liver and reduced grafts (74%, 
71% and 65%, respectively). Domino transplant is rarely used in pediatric patients. 
 
Mortality after LT 
While 1 year patient survival was 81% between 1995 and 1999, it has dramatically improved 
to reach 86% after 2010 (Figure 4). The critical period for post-LT outcome is represented by 
the first year: 46% of deaths and 67% of re-LT occur within the first year after LT (Figure 
15). In 44% of cases, re-LT is indicated in the month after primary LT, and more than a half 
(59%) of patients who die, do so within the 6 months after LT. 
Data represented in figure 16 correspond to the distribution of main causes of death according 
to the time of their incidence. Main causes of death in the 28,637 patients who died after 
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primary LT or Re-LT were differently distributed. Whereas death from primary graft non-
function or dysfunction, infections and technical (biliary or vascular) complications were 
more frequent within the first 6 months post-LT, tumor or non-tumor recurrence and tumor 
de novo were more frequent after the first month. Interestingly, the proportion of tumor and 
non-tumor recurrences as a cause of death is decreasing during the last years. 
 
Re-transplantation 
Five-year graft survival rates following a second and a third LTs were 48% and 42% 
respectively, significantly lower than those for primary LT (66% - P<0.0001) (Figure 17). 
Re-LT was indicated in 8,482 cases mainly for primary non-function, technical complications 
(biliary or vascular) and rejection within the first month post-LT. Tumor or non-tumor 
recurrences and de novo tumor were more frequent after the first month (Figure 18). Late re-
LT, more than 1 month after the first LT, has a significantly better graft survival than early 
re-LT performed within the month after the first LT (50% vs. 45% at 5 years, p<0.0001) 
(Figure 19). Re-LT which is mostly used in young patients (Figure 3A) has declined during 
the last decade (Figure 3B). Interestingly, tumor causes and non-tumor recurrence are 
decreasing during the last years, whereas technical complications, primary graft non-function 
or dysfunction and infection are increasing. 
 
Waiting time 
When more than 90% of candidates waited less than 3 months in the 80s, they represented 
70% in the 90s and slightly more than a half since 2000. This evolution is likely due to three 
main reasons: the increase of the number of candidates for transplantation following the 
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advent of more and more effective immunosuppressive treatments, the scarcity of grafts and 
the use of the MELD which gives priority to the sickest candidates. The 5-year survival of 
patients who have spent less than 3 months on the waiting list, certainly because they were 
more severe, was 70%, 5% lower than that of all the other groups of waiting times in the list 
(p<0.0001).  
 
DISCUSSION 
The ELTR data provides a descriptive overview of the overall situation of liver 
transplantation in Europe. There is of course heterogeneity in the policies in the 29 
contributing countries. This manuscript summarizes the results as a whole, and represents a 
kind of freeze-frame rather than a generalized statement for Europe. At the same time, the 
ELTR remains the unique entity capable of providing such statistics, capable of giving a 
global snapshot of the European experience, and helping to identify important trends that may 
guide further practice. 
Liver transplantation has become the best, if not the only effective treatment for severe 
irreversible liver disease. More than 7,000 LTs are performed annually in Europe, and the 
results look satisfactory at 5 years (71% survival) with still a room for improvement at long-
term (61% at 10 years and 41% at 20 years). The demand far exceeds the availability of 
organs for transplantation. It is therefore essential to continue to promote organ donation in 
Europe in order to avoid mortality on the waiting list, and a “drastic” selection of candidates. 
By allowing the transplant of the sickest candidates first, the MELD score has dramatically 
decreased the risk of death on the waiting list. However, the post-LT survival of high MELD 
score patients is less optimal, mostly for those with MELD score at transplant higher than 40. 
It also appears essential to continue to improve the perioperative management of LT at all 
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levels, along with a better prevention of long-term complications. The data provided by the 
ELTR are a basis to target the timing, and fields to improve the results. 
The main indication for LT is cirrhosis with end stage liver disease. However its proportion is 
decreasing continuously as compared to HCC. Fulminant hepatitis of unknown cause is also 
declining. Such relative diminution of cirrhosis is mainly related to the accelerated decline in 
HCV indications as a result of effective direct-acting antiviral drugs [17]. Thus, hundreds of 
liver grafts every year are becoming available for indications other than HCV. Even though 
NASH related cirrhosis is still less frequent in Europe compared to the US, it is anticipated to 
become the leading indication for liver transplantation within the next decade.  
In terms of results, all the indications have shown an improvement of survival especially 
HCC, mainly due to a better selection of patients, and the increasing effectiveness of down-
staging techniques [18]. The ELTR cohort of patients has also established that some rare 
malignant tumours like hepatic hemangiosarcoma should be considered absolute 
contraindications for LT [19], while others like hereditary hemorrhagic telangiectasia [8] or 
hepatic epithelioid hemangio-endothelioma represent a good indication even in the presence 
of limited extrahepatic disease [12, 24]. 
The average age of transplanted recipients has increased steadily during the last decade and a 
third of patients transplanted nowadays are > 60 years. Noteworthy, LT can offer a 10 
additional year benefit to 40% of septuagenarians. Also, an increasing number of transplanted 
liver grafts are coming from older donors with in most cases, the application of the old-to-old 
rule concerning the donor to recipient matching. 
Alternatives to the conventional DBD full size graft are increasingly used in Europe. Split 
liver and living donation are increasingly used both in adult and pediatric LT, and DCD grafts 
are mostly used in adults with quite good survival results. Domino and reduced livers seem to 
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be gradually disappearing. Optimization of donor management and organ preservation, offers 
the most realistic way to improve both the quality and pool of current organs. While only UW 
solution was used before 2000, an increasing number of new solutions are available today; 
the choice in preservation solution may have an independent impact on graft survival [25]. 
Also, while the introduction of cyclosporine and more recently Tacrolimus optimised 
immunosuppressive protocols, there is still room for improvement as recently shown by the 
use of prolonged release tacrolimus [26]. 
As a cause of graft loss, technical complications, primary graft non-function or dysfunction 
and infection are increasing, relatively. This could be related to the increasing use of marginal 
grafts coming from expanded donor criteria. Conversely, de novo tumor and non-tumor 
recurrence as cause of graft loss or mortality are decreasing during the last years. 
There are some limitations to our study. Data quality, reliability and representativeness is an 
everyday concern for the ELTR since its creation in 1986. With this constantly in mind, the 
ELTR has implemented several procedures and adapted them all along the years to control 
the quality of data, from collection, to statistical analysis. However, biases may persist as for 
all observational studies; therefore, the interpretation of these descriptive data must be done 
with caution.  Lost-to-follow-up (LTFU) patients are a real problem in the reported outcome. 
It is mainly related to the increasing number of transplanted patients who move to another 
place within a country or outside the country. More than 72% of ELTR data are shared with 
official OSOs who have setup a drastic tracking procedure to minimize the rate of LTFU. The 
remaining 28% who enter the data directly in our platform are regularly invited to consult the 
dynamically updated list of queries to solve all discrepancies and to report a recent patient 
follow-up.  
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By the prospective evaluation of almost all patients transplanted in Europe since the last fifty 
years, the ELTR provides valuable data concerning the evolution of LT, the dynamic changes 
in indications, in donor and recipients profile, as well as in preservation, technical aspects and 
post-transplant management. This data can help refine the indications for transplant in rare 
diseases, and establish new guidelines, while targeting the real fields which need 
improvement in order to optimize the results of liver transplantation.  
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LEGENDS  
 
Table 1: Primary indication of LT in Europe and the corresponding graft and patient 
survival rate. 
Figure 1: Number of LTs performed in each country, overall and living related liver 
transplantation (LRLT)(May 1968 – December 2016). 
Figure 2: Evolution of 147,161 LTs performed in Europe since May 1968. 
Figure 3: Evolution of indication according to three eras. 
The legends of the remaining figures are in the top of each figure. 
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Figure 19 
 
From 1988 to 2016 
 
Last 15 years 
Indication of LT 
N 
patients 
% of the 
disease 
% of 
the 
Total 
Survival 
rate N 
1 
year 
5 
years 
10 
years 
15 
years 
20 
years 
 
N 
patients 
% of the 
disease 
% of 
the 
Total 
Survival 
rate N 
1 
year 
5 
years 
10 
years 
15 
years 
                      
 
                  
Acute hepatic failure 9485   7% Graft 9268 66% 58% 52% 45% 37% 
 
6240   7% Graft 6080 70% 62% 55% 46% 
        Patient 9247 72% 65% 59% 54% 46% 
 
      Patient 6071 76% 69% 62% 55% 
                      
 
                  
Fulminant or Subfulminant 
hepatitis 7485   6% Graft 7291 66% 59% 53% 46% 38% 
 
4606   5% Graft 4466 71% 64% 57% 50% 
        Patient 7272 72% 66% 60% 54% 47% 
 
      Patient 4458 76% 70% 64% 57% 
Virus A 163 2% 0.1% Graft 160 61% 57% 52% 43% 32% 
 
111 2% 0.1% Graft 109 65% 61% 61%   
        Patient 159 63% 60% 56% 48% 43% 
 
      Patient 108 67% 62% 62%   
Virus B 917 12% 1% Graft 909 69% 62% 57% 50% 40% 
 
578 13% 1% Graft 571 74% 67% 64% 52% 
        Patient 905 75% 68% 63% 57% 47% 
 
      Patient 570 78% 73% 69% 61% 
Virus C 127 2% 0.1% Graft 125 65% 53% 39% 32% 25% 
 
80 2% 0.1% Graft 78 68% 50% 35%   
        Patient 125 72% 58% 42% 39% 27% 
 
      Patient 78 74% 54% 40%   
Virus D 14 0.2% 0.01% Graft 14 76% 67% 46% 46% 46% 
 
4 0.1% 0.004% Graft 4 100% 100% 67% 67% 
        Patient 14 76% 67% 56% 56% 56% 
 
      Patient 4 100% 100% 100% 100% 
Other known 797 11% 1% Graft 776 68% 61% 56% 49% 40% 
 
565 12% 1% Graft 547 71% 64% 57%   
        Patient 776 73% 68% 64% 55% 48% 
 
      Patient 547 76% 71% 64%   
Other unknown 3647 49% 3% Graft 3585 65% 58% 53% 46% 39% 
 
1966 43% 2% Graft 1922 71% 65% 59% 50% 
        Patient 3576 71% 65% 60% 55% 48% 
 
      Patient 1918 77% 71% 65% 57% 
Paracetamol 743 10% 1% Graft 671 69% 59% 50% 45% 32% 
 
531 12% 1% Graft 477 74% 64% 53% 43% 
        Patient 668 74% 65% 58% 54% 43% 
 
      Patient 476 78% 70% 63% 59% 
Other drug related: specify 715 10% 1% Graft 692 68% 62% 49% 44% 35% 
 
472 10% 1% Graft 461 72% 66% 56% 56% 
        Patient 691 72% 67% 56% 50% 42% 
 
      Patient 461 77% 71% 61% 61% 
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Toxic (non drug) 362 5% 0.3% Graft 359 63% 58% 51% 44% 29% 
 
299 6% 0.3% Graft 297 63% 58% 48% 48% 
        Patient 358 68% 64% 58% 51% 45% 
 
      Patient 296 68% 63% 54% 54% 
                      
 
                  
Traumatic acute hepatic 
failure  430   0.3% Graft 430 48% 39% 35% 31% 31% 
 
346   0.4% Graft 346 52% 41% 36%   
        Patient 429 57% 48% 44% 43% 43% 
 
      Patient 346 61% 51% 44%   
Post operative 173 40% 0.1% Graft 173 30% 20% 17%     
 
138 40% 0.2% Graft 138 33% 21% 17%   
        Patient 173 45% 34% 29% 24% 24% 
 
      Patient 138 48% 38% 30%   
Post traumatic 257 60% 0.2% Graft 257 61% 52% 48% 45% 45% 
 
208 60% 0.2% Graft 208 65% 55% 49%   
        Patient 256 65% 57% 54% 54% 54% 
 
      Patient 208 69% 60% 54%   
                      
 
                  
Subacute hepatic failure 1570   1%               
 
1288   1%             
Virus A 10 1% 0.01% Graft 10 67% 50%       
 
8 1% 0.01% Graft 8 71% 48%     
        Patient 10 67% 50%       
 
      Patient 8 71% 48%     
Virus B 130 8% 0.1% Graft 127 80% 65% 54% 20%   
 
113 9% 0.1% Graft 111 80% 68% 63%   
        Patient 127 85% 67% 61% 49%   
 
      Patient 111 85% 72% 66% 66% 
Virus C 184 12% 0.1% Graft 184 75% 56% 32% 18%   
 
161 13% 0.2% Graft 161 75% 55% 33%   
        Patient 183 78% 60% 36% 28%   
 
      Patient 160 79% 58% 34%   
Virus D 6 0.4% 0.005% Graft 6 67% 67% 67%     
 
4 0.3% 0.004% Graft 4 75% 75% 75%   
        Patient 6 83% 83% 56%     
 
      Patient 4 75% 75% 75%   
Other known 62 4% 0.05% Graft 61 76% 66% 66% 66% 66% 
 
54 4% 0.1% Graft 53 80% 68% 68%   
        Patient 61 79% 71% 64% 64% 64% 
 
      Patient 53 84% 74% 63%   
Other unknown 278 18% 0.2% Graft 267 77% 67% 62% 55% 45% 
 
207 16% 0.2% Graft 198 80% 71% 67% 58% 
        Patient 267 81% 75% 71% 65% 53% 
 
      Patient 198 84% 79% 76% 64% 
Paracetamol 5 0.3% 0.004% Graft 5 67% 67%       
 
4 0.3% 0.004% Graft 4 100% 100%     
        Patient 5 67% 67%       
 
      Patient 4 100% 100%     
Other drug related: specify 60 4% 0.05% Graft 56 62% 55% 49% 41% 41% 
 
51 4% 0.1% Graft 47 66% 57% 53%   
        Patient 56 70% 65% 56% 49% 49% 
 
      Patient 47 70% 65% 55%   
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Toxic (non drug) 24 2% 0.02% Graft 23 78% 68% 54% 27%   
 
17 1% 0.02% Graft 16 87% 80% 80%   
        Patient 23 78% 73% 58% 58%   
 
      Patient 16 87% 87% 87%   
Other acute hepatic failure: 
specify 811 52% 1% Graft 808 65% 54% 46% 40% 29% 
 
669 52% 1% Graft 666 67% 53% 46% 25% 
        Patient 808 72% 63% 55% 51% 45% 
 
      Patient 666 74% 62% 54% 48% 
                      
 
                  
Fulminant or subfulminant 
or subacute hepatitis 11625   9%               
 
7638   8%             
Viral 1551 13% 1% Graft 1535 70% 60% 53% 45% 36% 
 
1054 14% 1% Graft 1046 73% 63% 57% 46% 
        Patient 1529 75% 66% 58% 52% 43% 
 
      Patient 1043 78% 68% 61% 55% 
Virus B 1047 9% 1% Graft 1036 71% 62% 57% 49% 40% 
 
691 9% 1% Graft 682 75% 67% 64% 51% 
        Patient 1032 76% 69% 63% 57% 47% 
 
      Patient 681 80% 73% 69% 61% 
Drug-related 1523 13% 1% Graft 1424 68% 60% 50% 44% 34% 
 
1058 14% 1% Graft 989 73% 65% 55% 50% 
        Patient 1420 73% 66% 57% 52% 43% 
 
      Patient 988 77% 70% 62% 60% 
Paracetamol 748 6% 1% Graft 676 69% 59% 50% 45% 32% 
 
535 7% 1% Graft 481 75% 64% 53% 43% 
        Patient 673 74% 65% 58% 54% 43% 
 
      Patient 480 78% 70% 63% 59% 
Other drugs 775 7% 1% Graft 748 68% 61% 49% 44% 35% 
 
523 7% 1% Graft 508 72% 65% 56% 56% 
        Patient 747 72% 66% 56% 50% 42% 
 
      Patient 508 76% 70% 61% 61% 
Toxic (non drug) 386 3% 0.3% Graft 382 64% 59% 51% 44% 29% 
 
316 4% 0.3% Graft 313 64% 59% 49% 46% 
        Patient 381 69% 65% 58% 51% 45% 
 
      Patient 312 69% 65% 56% 56% 
Unknown or others 5595 48% 4% Graft 5497 66% 59% 53% 47% 39% 
 
3461 45% 4% Graft 3386 71% 63% 57% 46% 
        Patient 5488 72% 66% 61% 55% 48% 
 
      Patient 3382 77% 70% 64% 55% 
                      
 
                  
Cholestatic disease 13241   10% Graft 12917 82% 73% 62% 50% 38% 
 
8439   9% Graft 8242 84% 74% 63% 52% 
        Patient 12883 87% 79% 71% 59% 46% 
 
      Patient 8221 90% 81% 73% 62% 
Secondary biliary cirrhosis 976 7% 1% Graft 955 72% 62% 54% 47% 39% 
 
693 8% 1% Graft 679 73% 62% 54% 49% 
        Patient 955 79% 69% 62% 56% 48% 
 
      Patient 679 80% 69% 63% 58% 
Primary biliary cholangitis 5865 44% 5% Graft 5698 83% 76% 66% 54% 41% 
 
3050 36% 3% Graft 2971 86% 78% 68% 59% 
        Patient 5688 87% 80% 71% 58% 45% 
 
      Patient 2966 90% 83% 74% 64% 
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Primary sclerosing cholangitis 5786 44% 5% Graft 5682 83% 71% 58% 45% 31% 
 
4248 50% 5% Graft 4172 85% 73% 59% 46% 
        Patient 5663 89% 80% 71% 60% 46% 
 
      Patient 4160 91% 82% 74% 60% 
Other cholestatic disease: 
specify 614 5% 0.5% Graft 582 80% 74% 68% 58% 50% 
 
448 5% 0.5% Graft 420 79% 71% 66% 62% 
        Patient 577 86% 82% 78% 69% 64% 
 
      Patient 416 86% 80% 77% 71% 
                      
 
                  
Congenital biliary disease 6397   5% Graft 6248 82% 77% 73% 68% 63% 
 
4274   5% Graft 4180 85% 81% 77% 68% 
        Patient 6234 88% 85% 83% 80% 76% 
 
      Patient 4174 91% 88% 87% 85% 
Caroli disease 258 4% 0.2% Graft 257 81% 74% 66% 57% 52% 
 
207 5% 0.2% Graft 206 82% 74% 62%   
        Patient 257 89% 84% 80% 70% 66% 
 
      Patient 206 90% 86% 78% 78% 
Extrahepatic biliary atresia 5232 82% 4% Graft 5107 82% 77% 74% 70% 64% 
 
3403 80% 4% Graft 3326 86% 82% 78% 74% 
        Patient 5095 89% 85% 83% 81% 78% 
 
      Patient 3322 92% 89% 88% 86% 
Congenital biliary fibrosis 194 3% 0.2% Graft 192 80% 77% 67% 63% 61% 
 
138 3% 0.2% Graft 136 83% 78% 66% 66% 
        Patient 192 88% 85% 75% 71% 69% 
 
      Patient 136 90% 88% 75% 75% 
Choledocal cyst 41 1% 0.03% Graft 41 87% 80% 54% 36%   
 
21 0.5% 0.02% Graft 21 79% 63% 42%   
        Patient 41 87% 87% 76% 76%   
 
      Patient 21 79% 79% 59%   
Alagille syndrome 338 5% 0.3% Graft 335 82% 77% 74% 69% 69% 
 
261 6% 0.3% Graft 258 85% 81% 79% 75% 
        Patient 335 88% 84% 80% 77% 72% 
 
      Patient 258 90% 87% 85% 80% 
Other congenital biliary 
disease: specify 334 5% 0.3% Graft 316 83% 75% 68% 54% 44% 
 
244 6% 0.3% Graft 233 83% 75% 70% 21% 
        Patient 314 88% 81% 78% 68% 62% 
 
      Patient 231 89% 83% 82% 75% 
                      
 
                  
Cirrhosis 64166   50% Graft 63140 80% 67% 55% 43% 32% 
 
45566   50% Graft 44806 82% 68% 55% 42% 
        Patient 63062 84% 71% 59% 47% 36% 
 
      Patient 44758 85% 72% 59% 46% 
Alcoholic cirrhosis 24380 38% 19% Graft 24030 82% 70% 55% 41% 29% 
 
18135 40% 20% Graft 17849 83% 71% 55% 40% 
        Patient 24005 85% 74% 58% 43% 31% 
 
      Patient 17830 86% 75% 59% 43% 
Autoimmune Cirrhosis 2929 5% 2% Graft 2850 81% 71% 60% 48% 38% 
 
2027 4% 2% Graft 1978 83% 74% 63% 45% 
        Patient 2843 86% 77% 68% 57% 48% 
 
      Patient 1974 88% 80% 72% 57% 
Virus B related cirrhosis 5822 9% 5% Graft 5746 80% 70% 64% 56% 48% 
 
3826 8% 4% Graft 3774 82% 72% 66% 57% 
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        Patient 5739 84% 74% 68% 61% 52% 
 
      Patient 3770 86% 76% 70% 62% 
Virus C related cirrhosis 15187 24% 12% Graft 15062 77% 60% 47% 37% 26% 
 
10495 23% 12% Graft 10396 78% 59% 46% 36% 
        Patient 15051 80% 64% 52% 41% 30% 
 
      Patient 10387 81% 64% 51% 40% 
Virus BD related cirrhosis 1939 3% 2% Graft 1899 89% 84% 79% 74% 67% 
 
1431 3% 2% Graft 1403 89% 84% 79% 75% 
        Patient 1895 92% 88% 84% 81% 73% 
 
      Patient 1401 93% 89% 83% 78% 
Virus BC related cirrhosis 829 1% 1% Graft 819 78% 64% 54% 42% 31% 
 
559 1% 1% Graft 552 80% 66% 54% 34% 
        Patient 818 82% 70% 60% 47% 33% 
 
      Patient 551 83% 71% 60% 39% 
Virus BCD related cirrhosis 174 0.3% 0.1% Graft 170 88% 78% 62% 47% 47% 
 
134 0.3% 0.1% Graft 130 88% 78% 67%   
        Patient 170 90% 80% 67% 45% 45% 
 
      Patient 130 89% 81% 69%   
Virus related cirrhosis-Other 
viruses: specify 1994 3% 2% Graft 1780 83% 64% 49% 35% 24% 
 
1353 3% 1% Graft 1208 86% 66% 52% 39% 
        Patient 1766 85% 68% 54% 40% 27% 
 
      Patient 1203 89% 71% 57% 44% 
Combined virus C and 
alcoholic cirrhosis 1996 3% 2% Graft 1980 82% 65% 50% 36% 24% 
 
1531 3% 2% Graft 1515 83% 66% 51% 38% 
        Patient 1980 85% 69% 55% 41% 27% 
 
      Patient 1516 86% 70% 56% 44% 
Combined virus B and 
alcoholic cirrhosis 489 1% 0.4% Graft 485 87% 74% 61% 53% 53% 
 
382 1% 0.4% Graft 379 88% 77% 68%   
        Patient 484 90% 78% 64% 55% 55% 
 
      Patient 379 91% 80% 70%   
Post hepatitic cirrhosis-Drug 
related 77 0.1% 0.1% Graft 77 78% 63% 46% 33%   
 
44 0.1% 0.05% Graft 44 84% 65%     
        Patient 77 79% 67% 52% 34%   
 
      Patient 44 84% 70% 34%   
Other cirrhosis: specify 2732 4% 2% Graft 2728 77% 64% 55% 47% 38% 
 
1841 4% 2% Graft 1837 78% 66% 55% 45% 
        Patient 2727 81% 69% 59% 51% 42% 
 
      Patient 1836 83% 71% 59% 48% 
Cryptogenic (unknown) 
cirrhosis 5618 9% 4% Graft 5514 78% 67% 56% 46% 34% 
 
3808 8% 4% Graft 3741 80% 69% 57% 45% 
        Patient 5507 81% 72% 61% 50% 37% 
 
      Patient 3737 83% 73% 61% 47% 
                      
 
                  
Primary liver tumors 21135   17% Graft 20976 81% 60% 47% 36% 28% 
 
17329   19% Graft 17206 83% 64% 49% 37% 
        Patient 20971 84% 64% 50% 39% 31% 
 
      Patient 17202 87% 67% 53% 40% 
Hepatocellular carcinoma and 
cirrhosis 18349 87% 14% Graft 18225 82% 62% 48% 36% 28% 
 
15617 90% 17% Graft 15510 84% 65% 49% 38% 
        Patient 18220 86% 66% 51% 39% 31% 
 
      Patient 15506 87% 68% 53% 40% 
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Hepatocellular carcinoma and 
non cirrhotic liver 734 3% 1% Graft 726 72% 49% 34% 24% 18% 
 
425 2% 0.5% Graft 423 81% 61% 44%   
        Patient 726 77% 52% 37% 27% 20% 
 
      Patient 423 87% 66% 48% 24% 
Hepatocellular carcinoma - 
Fibrolamellar 51 0.2% 0.04% Graft 51 76% 38% 33% 27% 27% 
 
26 0.2% 0.03% Graft 26 85% 45%     
        Patient 51 80% 41% 36% 36% 36% 
 
      Patient 26 88% 47%     
Biliary tract carcinoma 
(Klatskin) 395 2% 0.3% Graft 394 65% 34% 26% 16% 13% 
 
245 1% 0.3% Graft 244 67% 35% 25%   
        Patient 394 72% 41% 35% 24% 21% 
 
      Patient 244 76% 47% 41%   
Hepatic cholangiocellular 
carcinoma 530 3% 0.4% Graft 526 66% 32% 23% 16% 14% 
 
306 2% 0.3% Graft 306 73% 40% 31% 17% 
        Patient 526 69% 33% 25% 19% 15% 
 
      Patient 306 77% 42% 32% 22% 
Hepatoblastoma 377 2% 0.3% Graft 372 83% 75% 71% 70% 61% 
 
330 2% 0.4% Graft 325 84% 77% 73% 73% 
        Patient 372 87% 80% 77% 75% 66% 
 
      Patient 325 88% 83% 79% 79% 
Epithelioid 
hemangioendothelioma 216 1% 0.2% Graft 213 85% 72% 67% 61% 58% 
 
161 1% 0.2% Graft 158 85% 73% 65% 60% 
        Patient 213 90% 77% 71% 67% 60% 
 
      Patient 158 91% 79% 71% 65% 
Angiosarcoma 17 0.1% 0.01% Graft 17 35%         
 
3 0.02% 0.003% Graft 3 67%       
        Patient 17 38%         
 
      Patient 3 67%       
Other liver malignancies: 
specify 466 2% 0.4% Graft 452 70% 46% 40% 33% 28% 
 
216 1% 0.2% Graft 211 82% 62% 57%   
        Patient 452 73% 49% 44% 36% 31% 
 
      Patient 211 85% 65% 62%   
                      
 
                  
Secondary liver tumors 639   0.5% Graft 636 75% 48% 32% 24% 19% 
 
395   0.4% Graft 393 79% 57% 44% 33% 
        Patient 636 80% 52% 34% 26% 21% 
 
      Patient 393 85% 61% 46% 36% 
Carcinoid 341 53% 0.3% Graft 339 78% 52% 34% 24% 19% 
 
185 47% 0.2% Graft 183 83% 64% 51% 38% 
        Patient 339 82% 55% 36% 27% 22% 
 
      Patient 183 87% 67% 54% 41% 
Other neuroendocrine 188 29% 0.1% Graft 188 74% 51% 40% 34%   
 
140 35% 0.2% Graft 140 76% 56% 44% 36% 
        Patient 188 80% 56% 43% 35%   
 
      Patient 140 83% 61% 45% 37% 
Colorectal 73 11% 0.1% Graft 72 73% 24% 3%     
 
53 13% 0.1% Graft 53 81% 24%     
        Patient 72 80% 26% 3%     
 
      Patient 53 85% 29%     
GI non colorectal 18 3% 0.01% Graft 18 60% 35% 20% 10%   
 
8 2% 0.01% Graft 8 45% 23% 23% 23% 
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        Patient 18 60% 35% 20% 10%   
 
      Patient 8 45% 23% 23% 23% 
Non gastrointestinal 19 3% 0.01% Graft 19 61% 41% 20%     
 
9 2% 0.01% Graft 9 76% 57%     
        Patient 19 72% 50% 27%     
 
      Patient 9 100% 80%     
                      
 
                  
Metabolic disease 7414   6% Graft 7188 82% 73% 64% 55% 48% 
 
5336   6% Graft 5166 83% 74% 63% 52% 
        Patient 7163 87% 79% 71% 63% 56% 
 
      Patient 5147 88% 80% 71% 60% 
Wilson disease 1241 17% 1% Graft 1200 83% 78% 71% 64% 56% 
 
904 17% 1% Graft 879 85% 79% 72% 65% 
        Patient 1191 89% 86% 81% 76% 69% 
 
      Patient 875 92% 87% 82% 77% 
Hemochromatosis 622 8% 0.5% Graft 610 74% 63% 48% 36% 28% 
 
399 7% 0.4% Graft 390 77% 65% 47% 40% 
        Patient 609 77% 66% 51% 38% 29% 
 
      Patient 389 80% 69% 50% 41% 
Alpha-1 - Antitrypsin 
deficiency 717 10% 1% Graft 678 83% 75% 66% 58% 44% 
 
478 9% 1% Graft 457 84% 76% 68% 54% 
        Patient 678 87% 81% 72% 65% 56% 
 
      Patient 457 88% 81% 73% 61% 
Glycogen storage disease 145 2% 0.1% Graft 142 87% 84% 77% 68% 68% 
 
118 2% 0.1% Graft 115 88% 83% 69%   
        Patient 142 94% 92% 86% 76% 76% 
 
      Patient 115 95% 92% 81%   
Homozygous 
Hypercholesterolemia 36 0.5% 0.03% Graft 36 86% 81% 65% 65% 65% 
 
29 1% 0.03% Graft 29 85% 80%     
        Patient 36 86% 81% 81% 81% 81% 
 
      Patient 29 85% 80%     
Tyrosinemia 122 2% 0.1% Graft 119 85% 75% 73% 71% 65% 
 
65 1% 0.1% Graft 62 87% 84% 84%   
        Patient 118 91% 86% 84% 84% 84% 
 
      Patient 62 90% 87% 87%   
Familial amyloidotic 
polyneuropathy 1261 17% 1% Graft 1241 82% 73% 62% 50% 38% 
 
866 16% 1% Graft 847 83% 73% 62% 50% 
        Patient 1231 88% 79% 68% 56% 46% 
 
      Patient 837 90% 81% 69%   
Primary hyperoxaluria 332 4% 0.3% Graft 326 79% 72% 62% 53% 50% 
 
264 5% 0.3% Graft 258 78% 73% 61% 33% 
        Patient 326 84% 77% 68% 58% 58% 
 
      Patient 258 84% 79% 67% 25% 
Protoporphyria 19 0.3% 0.01% Graft 19 77% 77% 70% 61% 51% 
 
8 0.1% 0.01% Graft 8 69% 69%     
        Patient 19 77% 77% 70% 61% 51% 
 
      Patient 8 69% 69%     
Other porphyria 17 0.2% 0.01% Graft 17 81% 65% 65%     
 
13 0.2% 0.01% Graft 13 83% 83%     
        Patient 17 87% 65% 65%     
 
      Patient 13 91% 82%     
Non alcoholic steatohepatitis 
(NASH) 749 10% 1% Graft 706 83% 72% 51%     
 
748 14% 1% Graft 705 83% 72% 52%   
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        Patient 705 86% 75% 54%     
 
      Patient 704 86% 75% 55%   
Crigler-Najjar 93 1% 0.1% Graft 88 86% 74% 72% 72% 72% 
 
65 1% 0.1% Graft 60 84% 70% 66%   
        Patient 88 94% 89% 89% 89% 89% 
 
      Patient 60 95% 91% 91%   
Cystic fibrosis 277 4% 0.2% Graft 272 83% 68% 63% 57% 46% 
 
233 4% 0.3% Graft 228 86% 73% 68%   
        Patient 271 85% 74% 64% 57% 45% 
 
      Patient 227 88% 76% 70%   
Byler disease 251 3% 0.2% Graft 250 85% 81% 78% 71% 71% 
 
137 3% 0.2% Graft 136 88% 82% 74% 59% 
        Patient 250 94% 92% 89% 85% 85% 
 
      Patient 136 94% 92% 90% 79% 
Other metabolic disease 1532 21% 1% Graft 1484 81% 71% 63% 55% 49% 
 
1009 19% 1% Graft 979 83% 72% 63% 54% 
        Patient 1482 86% 77% 71% 63% 57% 
 
      Patient 977 88% 79% 72% 65% 
                      
 
                  
Budd Chiari 1069   1% Graft 1052 73% 65% 57% 49% 39% 
 
715   1% Graft 704 77% 67% 58% 49% 
        Patient 1051 79% 72% 65% 57% 49% 
 
      Patient 704 82% 74% 65% 57% 
                      
 
    0%             
                      
 
                  
Benign liver tumors or 
Polycystic disease 1824   1% Graft 1804 85% 80% 70% 60% 52% 
 
1516   2% Graft 1499 87% 81% 71% 60% 
        Patient 1804 88% 84% 75% 65% 56% 
 
      Patient 1499 90% 86% 76% 64% 
Hepatic adenoma 38 2% 0.03% Graft 38 65% 47% 40% 40% 40% 
 
30 2% 0.03% Graft 30 70% 44% 44%   
        Patient 38 71% 55% 55% 55% 55% 
 
      Patient 30 73% 52% 52%   
Adenomatosis 51 3% 0.04% Graft 49 81% 81% 81% 81%   
 
45 3% 0.05% Graft 43 81% 81% 81%   
        Patient 49 87% 87% 87% 87%   
 
      Patient 43 88% 88% 88%   
Hemangioma 71 4% 0.1% Graft 71 75% 69% 64% 64% 64% 
 
45 3% 0.05% Graft 45 73% 64% 64% 64% 
        Patient 71 80% 77% 71% 71% 71% 
 
      Patient 45 75% 69% 69% 69% 
Focal nodular hyperplasia 12 1% 0.01% Graft 12 75% 64% 21%     
 
10 1% 0.01% Graft 10 80% 80% 27%   
        Patient 12 92% 92% 32%     
 
      Patient 10 90% 90% 45%   
Polycystic disease 1493 82% 1% Graft 1478 87% 82% 73% 62% 52% 
 
1293 85% 1% Graft 1280 88% 83% 73% 61% 
        Patient 1478 90% 86% 78% 67% 54% 
 
      Patient 1280 91% 87% 79% 65% 
Nodular regenerative 
hyperplasia 25 1% 0.02% Graft 25 88% 71% 71% 36% 36% 
 
17 1% 0.02% Graft 17 100% 83% 83%   
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        Patient 25 88% 71% 71% 36% 36% 
 
      Patient 17 100% 83% 83%   
Other benign tumors: specify 134 7% 0.1% Graft 131 79% 71% 60% 49% 44% 
 
76 5% 0.1% Graft 74 82% 73% 56% 56% 
        Patient 131 83% 76% 66% 54% 49% 
 
      Patient 74 86% 79% 62% 62% 
                      
 
                  
Parasitic disease 101   0.1% Graft 101 77% 69% 58% 40% 20% 
 
71   0.1% Graft 71 81% 70% 70%   
        Patient 101 80% 72% 61% 45% 27% 
 
      Patient 71 84% 73% 73%   
Schistosomia (Bilharzia) 2 2% 0.002% Graft 2 50% 50% 50% 50%   
 
1 1% 0.001% Graft           
        Patient 2 50% 50% 50% 50%   
 
      Patient           
Alveolar echinococcosis 58 57% 0.05% Graft 58 88% 80% 66% 66%   
 
49 69% 0.1% Graft 49 90% 78% 78%   
        Patient 58 90% 81% 67% 67%   
 
      Patient 49 92% 80% 80%   
Cystic hydatidosis 11 11% 0.01% Graft 11 72% 57% 57% 29%   
 
8 11% 0.01% Graft 8 74% 49%     
        Patient 11 71% 57% 57% 28%   
 
      Patient 8 74% 49%     
Other parasitic disease: 
specify 30 30% 0.02% Graft 30 60% 56% 44% 22% 22% 
 
13 18% 0.01% Graft 13 60% 60% 60%   
        Patient 30 68% 64% 52% 33% 33% 
 
      Patient 13 69% 69% 69%   
                      
 
                  
Other liver disease 2380   2% Graft 2325 73% 64% 56% 50% 42% 
 
1302   1% Graft 1264 75% 67% 59% 43% 
        Patient 2318 77% 69% 61% 55% 47% 
 
      Patient 1263 80% 72% 64% 49% 
TPN-induced cholestasis 11 0.5% 0.01% Graft 11 71% 54%       
 
10 1% 0.01% Graft 10 68% 46%     
        Patient 11 71% 54%       
 
      Patient 10 68% 46%     
Hepatopulmonary syndrome 19 1% 0.01% Graft 18 78% 78%       
 
19 1% 0.02% Graft 18 78% 78%     
        Patient 18 78% 78%       
 
      Patient 18 78% 78%     
Other liver diseases. non-
specified 2350 99% 2% Graft 2296 73% 64% 56% 50% 42% 
 
1273 98% 1% Graft 1233 75% 67% 59% 43% 
        Patient 2289 77% 69% 61% 55% 47% 
 
      Patient 1232 80% 72% 64% 49% 
                      
 
                  
Total 127851   100%               
 
91183   100%             
 
Table 1  
